Navigation Links
Diffusion Pharmaceuticals Announces Issuance of U.S. Patent No. 7351844, Titled 'Bipolar Trans Carotenoid Salts and Their Uses,' for Its Family of First-In-Class Molecules

CHARLOTTESVILLE, Va., April 8, 2008 /PRNewswire/ -- Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing drugs utilizing a novel method of action that enhances oxygen diffusion, today announced that it has been granted U.S. patent no. 7,351,844 entitled "Bipolar Trans Carotenoid Salts and Their Uses." This patent includes claims to a family of first-in-class new chemical entities, known as trans biopolar carotenoid (or TBC) molecules. In addition, the Company also announced it has been granted corresponding patents from the South African and the New Zealand Patent Offices.

"The issuance of these patents is a vital step in our intellectual property development strategy, furthering our goal of bringing Diffusion Pharmaceutical's first-in-class therapeutics to market. Our highly unique compounds may one day treat patients with a broad range of disorders involving hypoxia," said David G. Kalergis, Diffusion's CEO.

In addition to these newly issued patents, the Company has also filed other U.S. patent applications and numerous corresponding foreign and national-stage applications in major international markets.

About Diffusion Pharmaceuticals LLC

Diffusion Pharmaceuticals LLC is a clinical-stage drug-development company commercializing a family of first-in-class drug candidates to treat serious or life-threatening medical conditions. These proprietary small molecules use a novel method of action to enhance oxygen diffusion to oxygen deprived (hypoxic) tissue. Potential clinical applications include cancer, critical care uses such as trauma, hemorrhage, stroke and heart attack, as well as chronic conditions such as peripheral arterial and vascular disease, cardiovascular disease, and respiratory disorders. Enhanced diffusion of oxygen into hypoxic tissue has an important application in oncology by improving the efficacy of radiation therapy in cancerous tumors. A Phase 1 study for its lead molecule, trans sodium crocetinate (TSC), in healthy subjects was successfully completed in 2007. The company is now initiating proof-of-concept and dose-finding studies in cancer patients undergoing radiation therapy and in peripheral arterial disease patients suffering from intermittent claudication. Diffusion Pharmaceuticals, which is privately held, is located in Charlottesville, Virginia. For more information, visit

SOURCE Diffusion Pharmaceuticals LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
2. BioSpace to Host Regeneron Pharmaceuticals Career Fair in Whippany, New Jersey
3. Microbia Announces Name Change to Ironwood Pharmaceuticals
4. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
5. Memory Pharmaceuticals Receives Nasdaq Notification
6. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
7. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
8. Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals
9. Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
10. VIA Pharmaceuticals Complies With NASDAQ Rule
11. Core Informatics Completes Successful LIMS Implementation for Progenics Pharmaceuticals
Post Your Comments:
(Date:6/27/2016)... 2016  Sequenom, Inc. (NASDAQ: SQNM ), ... through the development of innovative products and services, announced ... United States denied its petition to review ... Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") are not ... the Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories ...
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... , June 23, 2016 A person commits ... the crime scene to track the criminal down. ... U.S. Food and Drug Administration (FDA) uses DNA evidence to ... Sound far-fetched? It,s not. The FDA has ... to support investigations of foodborne illnesses. Put as simply as ...
Breaking Biology Technology:
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
(Date:3/18/2016)... -- --> --> Competitive ... Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance & Detection Systems ... security market and the continuing migration crisis in the ... has led visiongain to publish this unique report, which ... defence & security companies in the border security market ...
Breaking Biology News(10 mins):